October 25, 2018
Rose
The new $5,850 a year price tag is still higher than cost-effectiveness watchdogs recommend, but it's a big drop from the original $14,000 a year. Sales never took off for the drug, in part because patients balked at the cost. Meanwhile, FDA Commissioner Scott Gottlieb sounds an alarm over pricey new cancer treatments.
from Kaiser Health News https://ift.tt/2D4ynSv
October 25, 2018
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Hidden Dangers Of Dating Apps: Sex Offenders, Including Rapists, Are Using Them. Why Do Companies Allow It?- How Many Teens Have Died Preventable Deaths In Psychiatric Wards? The Answer Isn’t Easy To Find
- State Highlights: Lack Of Access To Clean Drinking Water Continues To Affect Non-White Communities In California; Mormon Church Agrees To Utah’s Ban On Conversion Therapy
- As Schools Move To Crack Down On Vaping, A New Problem Arises: Litter In The Shape Of Discarded Pods
- In Their Own Words: High School Class Of 2000 Alums Talk About What It Was Like To Be At Heart Of Opioid Epidemic
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment